Double-blind crossover study of chlorpromazine and lorazepam in the treatment of behavioral problems during treatment of children with acute lymphoblastic leukaemia receiving glucocorticoids.
Pelletier
G
G
Department of Psychiatry, Hôpital Ste-Justine, Montréal, Quebec, Canada. pelletgi@ere.umontreal.ca
Lacroix
Y
Y
Moghrabi
A
A
Robaey
P
P
D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002652:Child Behavior / Q000187:drug effects; D002653:Child Behavior Disorders / Q000139:chemically induced / Q000145:classification / Q000188:drug therapy*; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008140:Lorazepam / Q000009:adverse effects / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D005938:Glucocorticoids; D008140:Lorazepam; D002746:Chlorpromazine